Özet:

In primary immunodeficiencies, immunoglobulin therapy is applied to prevent infections.In recent years, subcutaneous treatment is preferred instead of intravenously.In this study, demographic and clinical characteristics of patients who underwent subcutaneous immunoglobulin treatment due to primary immunodeficiency in our center were given. The records of patients who underwent subcutaneous treatment with the diagnosis of primary immunodeficiency between 2014-2017 in the University of Eskişehir Osmangazi Faculty of Medicine Pediatric Allergy and Immunology clinic were analyzed retrospectively. 15 patients with primary immunodeficiency were included in the study.9 (60%) of the patients were male, their ages were determined as the lowest 10 months - the highest 15 years. Ataxia telangiectasia in three patients (20%), common variable immune deficiency in three (20%), X-linked agamaglobulinemia in three (20%), autosomal recessive agamaglobulinemia in one (6.6%), unclassified hypogamaglobulinemia in two (13.2%), transient hypogamaglobulinemia in one (6.6%), hyper IgE syndrome in one (6.6%) ,and hyper IgM syndrome in one (6.6%) detected.Two of the three patients (66.6%) who were followed with ataxia telangiectasia were hospitalized due to the infection they had in the first year of subcutaneous immunoglobulin treatment. All patients stated that they would prefer subcutaneous treatment in their follow-up. Consequently, subcutaneous immunoglobulin therapy is an effective, easy and safe option.

Anahtar Kelimeler: